OverviewSuggest Edit

Oramed Pharmaceuticals is a pharmaceutical company currently engaged in the research and development of innovative pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.

TypePublic
Founded2006
HQNew York, US
Websiteoramed.com

Latest Updates

Employees (est.) (Nov 2017)14(+17%)
Revenue (FY, 2019)$2.7 M(+11%)
Share Price (Aug 2020)$3.7 (-2%)
Cybersecurity ratingAMore

Key People/Management at Oramed Pharmaceuticals

Nadav Kidron

Nadav Kidron

Chief Executive Officer, President & Director
Miriam Kidron

Miriam Kidron

Chief Scientific Officer & Director
Josh Hexter

Josh Hexter

Chief Operating and Business Officer
Avi Gabay

Avi Gabay

CFO
Show more

Oramed Pharmaceuticals Office Locations

Oramed Pharmaceuticals has offices in New York and ירושלים
New York, US (HQ)
1185 6th Ave #228
ירושלים, IL (HQ)
Hi-Tech Park
Show all (2)

Oramed Pharmaceuticals Financials and Metrics

Oramed Pharmaceuticals Revenue

Oramed Pharmaceuticals's revenue was reported to be $2.70 m in FY, 2019
USD

Revenue (Q3, 2020)

681.0k

Net income (Q3, 2020)

2.3m

Market capitalization (12-Aug-2020)

87.3m

Closing stock price (12-Aug-2020)

3.7

Cash (31-May-2020)

9.3m

EV

78.1m
Oramed Pharmaceuticals's current market capitalization is $87.3 m.
Annual
USDFY, 2012FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

641.0k2.5m2.4m2.7m

Cost of goods sold

490.0k187.0k90.0k

Gross profit

151.0k2.3m2.6m

Gross profit Margin, %

24%92%97%
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

125.0k163.0k(610.0k)611.0k(617.0k)611.0k604.0k617.0k674.0k666.0k682.0k674.0k674.0k681.0k

Cost of goods sold

187.0k86.0k35.0k55.0k

Gross profit

(797.0k)531.0k639.0k611.0k

Gross profit Margin, %

131%86%95%92%
Annual
USDFY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.4m2.3m3.2m3.9m4.0m5.0m3.3m

Accounts Receivable

87.7k58.4k

Prepaid Expenses

2.3k90.1k127.0k198.0k159.0k574.0k1.0m

Current Assets

5.3m8.6m17.4m31.2m20.3m31.0m33.3m
Quarterly
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.3m)(4.2m)(5.7m)(11.0m)(10.5m)(12.7m)(14.4m)

Depreciation and Amortization

14.7k5.4k6.0k4.0k4.0k5.0k6.0k8.0k

Accounts Payable

203.1k(146.2k)475.0k

Cash From Operating Activities

(2.3m)(3.4m)(4.1m)(4.9m)4.7m(5.8m)(14.7m)(12.9m)
USDQ1, 2012

Financial Leverage

1.2 x
Show all financial metrics

Oramed Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Oramed Pharmaceuticals Online and Social Media Presence

Embed Graph

Oramed Pharmaceuticals News and Updates

Oramed Pharmaceuticals Issues Letter to Shareholders

NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following letter to shareholders from Chief...

Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the...

Oramed Pharmaceuticals Blogs

Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock

NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it intends to offer and sell shares of its common stock in an underwritten public o…

Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial

NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Primary endpoints successfully met Results confirm significant clinical benefits of ORMD-0801 at lower dose treatment 0.95% (0.81% placebo adjusted) A1C reduction in patients treated once daily at 8mg Excellent safety profile Paves the way for FDA discussions …

Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board

NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Board. Dr. Fleming is F…

i24news: New technology could revolutionize market of 500 million diabetes patients

CEO Nadav Kidron speaks with i24 News about the potential of oral insulin. Read and Watch here.   The post i24news: New technology could revolutionize market of 500 million diabetes patients appeared first on Oramed Pharmaceuticals.

Oramed Appoints Dr. Arie Mayer to Board of Directors

Dr. Mayer is the current Managing Director and Chairman of the Board of Merck Life Science Israel NEW YORK, Dec. 5, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery …

Oramed to Present a Scientific Poster at International Diabetes Federation Congress

NEW YORK, December 2, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it will present a scientific poster at the 2019 International Diabete…
Show more

Oramed Pharmaceuticals Frequently Asked Questions

  • When was Oramed Pharmaceuticals founded?

    Oramed Pharmaceuticals was founded in 2006.

  • Who are Oramed Pharmaceuticals key executives?

    Oramed Pharmaceuticals's key executives are Nadav Kidron, Miriam Kidron and Josh Hexter.

  • How many employees does Oramed Pharmaceuticals have?

    Oramed Pharmaceuticals has 14 employees.

  • What is Oramed Pharmaceuticals revenue?

    Latest Oramed Pharmaceuticals annual revenue is $2.7 m.

  • What is Oramed Pharmaceuticals revenue per employee?

    Latest Oramed Pharmaceuticals revenue per employee is $193.1 k.

  • Who are Oramed Pharmaceuticals competitors?

    Competitors of Oramed Pharmaceuticals include Rani Therapeutics, Gan & Lee Pharmaceuticals and Diasome.

  • Where is Oramed Pharmaceuticals headquarters?

    Oramed Pharmaceuticals headquarters is located at 1185 6th Ave #228, New York.

  • Where are Oramed Pharmaceuticals offices?

    Oramed Pharmaceuticals has offices in New York and ירושלים.

  • How many offices does Oramed Pharmaceuticals have?

    Oramed Pharmaceuticals has 2 offices.